Floatz logo

Temsirolimus

Recurrent Adult Brain Tumor

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

61 Active assets in the Recurrent Adult Brain Tumor cohort.

Asset / SponsorPhaseRating
Cediranib
M.D. Anderson Cancer Center
Phase 2BBB
Sorafenib
National Cancer Institute (NCI)
Phase 2BB
Bxcl501
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4BB
Vorinostat
H. Lee Moffitt Cancer Center and Research Institute
Phase 2BB
Nivolumab
InSightec
Phase 3BB

View all 50 →

Same molecule, other indications

Temsirolimus is also rated in:

gliosarcomaDormant
BBB
Indicative ·
74 / 100
View asset →
adult glioblastomaDormant
BBB
Indicative ·
74 / 100
View asset →
giant cell glioblastomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →